Growing by Sharing - Story of Ryvu and Selvita

Author(s): Magdalena Marciniak*

Journal Name: Technology Transfer and Entrepreneurship

Volume 7 , Issue 1 , 2020

Become EABM
Become Reviewer

Abstract:

Ryvu Therapeutics and Selvita originated in 2007, a time when drug discovery in Poland was still not pursued by industrial enterprises. For many years, both entities operated one company and were known under a common name Selvita S.A., combining their efforts on both innovative small-molecule therapeutics for oncology and expertise in Contract Research Services (CRO). Following more than a decade of such a hybrid business model, Selvita established a strong position in the field of drug discovery and built trust among partners, clients, and investors globally. This encouraged the leaders of the company to separate the two divisions into fully autonomous units, which in fact, had already been operating quite independently and both were successful in diverse areas of drug discovery activities. At the beginning of October 2019, two new companies were established and both parts were given independence and more opportunities for growth. Discovery and development engine was named as Ryvu Therapeutics, and the CRO part of the company remained with the name Selvita. To reach this stage, both the divisions went through an interesting journey together, supporting and strengthening each other for the benefit of both.

Keywords: Oncology, biotechnology, small molecules, Poland, ryvu therapeutics, selvita, cancer.

[1]
Pelish HE, Liau BB, Nitulescu II, et al. Mediator kinase inhibition further activates super-enhancer-associated genes in AML. Nature 2015; 526(7572): 273-6.
[http://dx.doi.org/10.1038/nature14904] [PMID: 26416749]
[2]
Wu M, Li C, Zhu X. FLT3 inhibitors in acute myeloid leukemia. J Hematol Oncol 2018; 11(1): 133.
[http://dx.doi.org/10.1186/s13045-018-0675-4] [PMID: 30514344]
[3]
An international perspective on advancing technologies and strategies for managing dual-use risks: report of a workshop. Drivers of international biotechnology development 2005; 35.
[4]
Boutard N, Białas A, Sabiniarz A, et al. Synthesis of amide and sulfonamide substituted N-aryl 6-aminoquinoxalines as PFKFB3 inhibitors with improved physicochemical properties. Bioorg Med Chem Lett 2019; 29(4): 646-53.
[http://dx.doi.org/10.1016/j.bmcl.2018.12.034] [PMID: 30626557]
[5]
Ashworth A, Lord CJ. Synthetic lethal therapies for cancer: Nat Rev Clin Oncol 2018; 15: 564-76.
[http://dx.doi.org/10.1038/s41571-018-0055-6] [PMID: 29955114]
[6]
Woo S-R. STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors. Immunity 2014; 41(5): 830-42.
[http://dx.doi.org/10.1016/j.immuni.2014.10.017] [PMID: 25517615]
[7]
H3 biomedicine and Selvita announce strategic collaboration to develop precision cancer medicines 2013..Available from:. http://eisai.mediaroom.com/ 2013-09-16-H3-Biomedicine-and-Selvita-Announce- Strategic-Collaboration-to-Develop-Precision- Cancer-Medicines
[8]
Merck and Selvita announce drug discovery collaboration 2015.Available from:. https://ryvu.com/2015/11/02/merck-and-selvita-announce-drug-discovery-collaboration/
[9]
Nowak M, Fabritius CH, Brzozka K, et al. Synthesis of amide and sulfonamide substituted N-aryl 6-aminoquinoxalines as PFKFB3 inhibitors with improved physicochemical properties. Bioorg & Med Chem Lett 2019; 29(4): 646-53.
[http://dx.doi.org/10.1016/j.bmcl.2018.12.034]
[10]
Felicitex Therapeutics and Selvita initiate strategic collaboration to target cancer quiescence 2014.Available from:. https://archiwum.selvita.com/news-events/news-releases/felicitex-therapeutics-and-selvita-initiate-strategic-collaboration-to-target-cancer-quiescence
[11]
SEL24/MEN1703 in patients with acute myeloid leukemia 2017.Available from:. https://clinicaltrials. gov/ct2/show/NCT03008187
[12]
Agarwal M, Brzózka K, Marshall WS. The therapy acceleration program (TAP) 2017.Available from:. https://www.lls.org/who-we-are/research-investment/tap
[13]
Rzymski T, Mikula M, Żyłkiewicz E, et al. SEL120-34A is a novel CDK8 inhibitor active in AML cells with high levels of serine phosphorylation of STAT1 and STAT5 transactivation domains. Oncotarget 2017; 8: 33779-95.Available from:. http://www. oncotarget.com/index.php?journal=oncotarget&page=article&op=view&path%5B%5D=16810
[14]
Alan A, Lord CJ. Synthetic lethal therapies for cancer: Nat Rev Clin Oncol 2018; 15: 564-76.
[http://dx.doi.org/10.1038/s41571-018-0055-6]
[15]
Woo SR, Fuertes MB, Corrales L, et al. STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors. Immunity 2014; 41(5): 830-42.
[http://dx.doi.org/10.1016/j.immuni.2014.10.017] [PMID: 25517615]
[16]
Hernandez S, Qing J, Kim JM, et al. The kinase activity of hematopoietic progenitor kinase 1 is essential for the regulation of T cell function. Cell Rep 2018; 25(1): 80-94.
[http://dx.doi.org/10.1016/j.celrep.2018.09.012] [PMID: 30282040]
[17]
Leone RD, Emens LA. Targeting adenosine for cancer immunotherapy. J Immunother Cancer 2018; 18(6): 57.
[http://dx.doi.org/10.1186/s40425-018-0360-8] [PMID: 29914571]
[18]
Management board report from activities of Selvita SA 2018.Available from:. https://static.igpw.pl/pliki/ raporty/1553752744-3371.pdf
[19]
Ryvu Therapeutics SA. SEL120 in patients with acute myeloid leukemia or high-risk myelodysplastic syndrome 2019.Available from:. https://clinicaltrials.gov/ct2/show/NCT04021368
[20]
Ryvu Therapeutics and Selvita announce registration of corporate split by the National Court Register of Poland 2019.Available from:. https://selvita.com/ news/ryvu-therapeutics-and-selvita-announce-regis- tration-of-corporate-split-by-the-national-court-register-of-poland/


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 7
ISSUE: 1
Year: 2020
Page: [33 - 47]
Pages: 15
DOI: 10.2174/2213809907666200320085519
Price: $25

Article Metrics

PDF: 6
HTML: 1